Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsFRA:CN2 93 PEG Ratio is 0.35 as of Jul. 22, 2026, which is 13% above its 10-year median of 0.31. GuruFocus rates FRA:CN2 with a GF Score™ of 93/100 and a GF Value™ of €20.73 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 93 Biotechnology companies, Catalyst Pharmaceuticals ranks better than 87.1% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Catalyst Pharmaceuticals's PEG Ratio or its related term are showing as below:
FRA:CN2'
s PEG Ratio Range Over the Past 10 Years
Min: 0.22 Med: 0.31 Max: 0.43
Current: 0.35
During the past 13 years, Catalyst Pharmaceuticals's highest PEG Ratio was 0.43. The lowest was 0.22. And the median was 0.31.
FRA:CN2's PEG Ratio is ranked better than 87.1% of 93
companies
in the Biotechnology industry
Industry Median: 1.97
vs FRA:CN2: 0.35
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Catalyst Pharmaceuticals (FRA:CN2) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Catalyst Pharmaceuticals PEG Ratio Related Terms
Catalyst Pharmaceuticals PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Catalyst Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Catalyst Pharmaceuticals (FRA:CN2) has a PEG Ratio of 0.35 as of Jul. 22, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Catalyst Pharmaceuticals and its competitors. This is 13% above median its historical median of 0.31. Over the past decade, Catalyst Pharmaceuticals' PEG Ratio has ranged from 0.22 to 0.43. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #12 out of 93 companies in the Biotechnology industry, placing it in the top 12.9%.
Is Catalyst Pharmaceuticals' PEG Ratio too high?
Catalyst Pharmaceuticals' current PEG Ratio of 0.35 is 13% above median its 10-year median of 0.31. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 0.43. The Biotechnology industry median PEG Ratio is 1.97. Catalyst Pharmaceuticals' value of 0.35 is 82.2% below this industry median. Based on the distribution chart, Catalyst Pharmaceuticals ranks #12 out of 93 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Catalyst Pharmaceuticals has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' PEG Ratio compare to CRNX and NAMS?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #12 out of 93 companies for PEG Ratio. This places Catalyst Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.97. Catalyst Pharmaceuticals' value of 0.35 is 82.2% below this benchmark. Historically, Catalyst Pharmaceuticals' own PEG Ratio has ranged from 0.22 to 0.43 over the past decade. While the company's 10-year median is 0.31 vs. the industry median of 1.97, Catalyst Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.97, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Catalyst Pharmaceuticals's current PEG Ratio of 0.35 is 82.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Catalyst Pharmaceuticals and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catalyst Pharmaceuticals's current PEG Ratio is 0.35, which is 13% above median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (FRA:CN2) is currently considered Significantly Overvalued. The stock's GF Value™ is €20.73, compared to a current price of €27.30 — trading 31.7% above its estimated fair value. The current PEG Ratio is 0.35, which is 13% above median its 10-year median of 0.31 and 82.2% below the Biotechnology industry median of 1.97. Catalyst Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Catalyst Pharmaceuticals (FRA:CN2), the current PEG Ratio is 0.35 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (FRA:CN2) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of €27.30 is trading 31.7% above its estimated GF Value™ of €20.73.
GuruFocus considers Catalyst Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:CN2:
PEG Ratio: 0.35 (13% above median its 10-year median of 0.31)
GF Value™: €20.73 vs. price of €27.30 (31.7% above fair value)
Industry Position: 82.2% below the Biotechnology median (#12 of 93)
No single metric tells the full story. See the FRA:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
93GF Score
Get the complete analysis for FRA:CN2
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CN2 has been successfully added to your 
